[go: up one dir, main page]

JP4138005B2 - トレオーメチルフェニデートの分割 - Google Patents

トレオーメチルフェニデートの分割 Download PDF

Info

Publication number
JP4138005B2
JP4138005B2 JP53159297A JP53159297A JP4138005B2 JP 4138005 B2 JP4138005 B2 JP 4138005B2 JP 53159297 A JP53159297 A JP 53159297A JP 53159297 A JP53159297 A JP 53159297A JP 4138005 B2 JP4138005 B2 JP 4138005B2
Authority
JP
Japan
Prior art keywords
threo
methylphenidate
treomethylphenidate
split
resolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53159297A
Other languages
English (en)
Other versions
JP2000506162A (ja
Inventor
ザバレー,フーシャン・シャーリアリ
Original Assignee
メデバ・ユアラプ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604943.2A external-priority patent/GB9604943D0/en
Application filed by メデバ・ユアラプ・リミテッド filed Critical メデバ・ユアラプ・リミテッド
Publication of JP2000506162A publication Critical patent/JP2000506162A/ja
Application granted granted Critical
Publication of JP4138005B2 publication Critical patent/JP4138005B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0004Crystallisation cooling by heat exchange
    • B01D9/0013Crystallisation cooling by heat exchange by indirect heat exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Read Only Memory (AREA)
  • Electrophonic Musical Instruments (AREA)

Description

発明の分野
この発明はトレオ−メチルフェニデートのジアステレオマー塩の晶化を経由する分割に関する。
発明の背景
メチルフェニデートはエリトロラセミ体とトレオラセミ体の混合物として最初に調製された。米国特許第2957880号明細書にはこの2種のラセミ体の混合物に関する研究結果が開示されており、治療的活性はトレオジアステレオマーにあることが明らかにされている。
トレオ−メチルフェニデートの分割は高価な分割剤である1,1’−ビナフチル−2,2’−ジイルヒドロジェンホスフェートを用いておこなうことができる。この方法はパトリックらによって最初に報告されたが[ザ・ジャーナル・オブ・ファーマコロジー・アンド・エクスペリメンタル・セラピューテックス、第241巻、第152頁〜第158頁(1987年)参照]、その後、この分野においては他の研究者によってこの方法は利用されている[例えば、アオヤマら、ジャーナル・オブ・クロマトグラフィー、第494巻、第420頁(1989年)参照]。この方法は米国特許第2957880号明細書に記載されている方法[エリトロ−メチルフェニデートの対応するアミド(即ち、R−CON2MeよりもR−CONR2)をアミド加水分解とベンジル中心における平衡化の前に酒石酸を用いて分割した後、得られたトレオ−酸をエステル化する方法]よりも効率的であることが明らかにされている。
この方法の改良された分割法がPCT/GB97/00185に記載されている。この改良分割法はPCT/GB97/00281に開示されているラセミ化法と組合せることができる。
発明の概要
この発明はトレオ−メチルフェニデートラセミ体が低コストの(−)−メントキシ酢酸(menthoxyacetic acid)を用いて分割できるという知見に基づいてなされたものである。
発明の説明
本発明方法は古典的な塩分割法の分野において当業者に一般的に知られている条件下でおこなってもよい。例えば、トレオ−メチルフェニデート遊離塩基と1モル当量の(−)−メントキシ酢酸を不活性有機溶剤中に加えた混合物を加熱後、冷却し、得られた沈澱物を濾取し、適当な溶剤で洗浄後、乾燥することによってd−トレオ−メチルフェニデートを98%eeで含有する塩を直接的に得ることができる。この方法はパトリックらによる前記の文献に記載されている方法、即ち、1,1’−ビナフチル−2,2’−ジイルヒドロジェンホスフェートを用いる方法に比べて著しく改良された方法である。何故ならば、後者の場合には、1回目の結晶化によって85〜90%eeの塩が得られるに過ぎず、このeeを95〜97%に高めるためには該塩の再結晶が必要だからである。95〜97%eeのレベルの光学純度は本発明の場合には1回の結晶化で達成することができ、しかも全収率はより高くなる。従って、本発明方法はパトリックらによる前記文献に記載の方法よりも効率的で経済的である。
(−)−メントキシ酢酸を用いるトレオ−メチルフェニデートの分割法を以下の実施例によって例証する。
実施例
dl−トレオ−メチルフェニデート(1.0g; 3.7mmol)を水(20ml)中に懸濁させた後、苛性溶液を用いて処理した。生成した遊離塩基をメチルt−ブチルエーテルを用いて抽出し(3×25ml)、抽出物をMgSO4を用いて乾燥させた後、蒸発処理に付すことによって軽油状物を得た。この軽油状物をイソプロピルアルコール(15ml)に溶解させて60℃まで加熱した。次いで、(−)−メントキシ酢酸(0.79g; 3.79mmol)をイソプロピルアルコール(5(ml)に溶解させた溶液を添加して60℃での加熱をさらに30分間続行した後、反応混合物を10℃まで徐冷した。得られた白色結晶性生成物を濾取し、冷イソプロピルアルコールを用いて洗浄後、乾燥処理に付すことによって所望の生成物を0.85g得た。塩クラッキング後のキラルHPLCによって測定したところによれば、このうちの47重量%は98%eeのd−トレオ−メチルフェニデートに相当した。

Claims (1)

  1. (−)−メントキシ酢酸を用いる古典的な塩分割法によっておこなう実質上単一の鏡像体であるd−トレオ−メチルフェニデートの製造法。
JP53159297A 1996-03-08 1997-03-07 トレオーメチルフェニデートの分割 Expired - Fee Related JP4138005B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9604943.2A GB9604943D0 (en) 1996-03-08 1996-03-08 Resolution
US1698696P 1996-05-07 1996-05-07
US60/016,986 1996-05-07
US9604943.2 1996-05-07
PCT/GB1997/000643 WO1997032851A1 (en) 1996-03-08 1997-03-07 Resolution of threo-methylphenidate

Publications (2)

Publication Number Publication Date
JP2000506162A JP2000506162A (ja) 2000-05-23
JP4138005B2 true JP4138005B2 (ja) 2008-08-20

Family

ID=26308891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53159297A Expired - Fee Related JP4138005B2 (ja) 1996-03-08 1997-03-07 トレオーメチルフェニデートの分割

Country Status (11)

Country Link
EP (1) EP0885191B1 (ja)
JP (1) JP4138005B2 (ja)
KR (1) KR100459149B1 (ja)
AT (1) ATE212336T1 (ja)
AU (1) AU700836B2 (ja)
CA (1) CA2243542C (ja)
DE (1) DE69710051T2 (ja)
DK (1) DK0885191T3 (ja)
ES (1) ES2173422T3 (ja)
PT (1) PT885191E (ja)
WO (1) WO1997032851A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US8552030B2 (en) 2009-05-07 2013-10-08 Malladi Drugs & Pharmaceuticals Ltd. Process for the preparation of d-threo-ritalinic acid hydrochloride by resolution of dl-threo-ritalinic acid using chiral carboxylic acid
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9028868B2 (en) 2011-03-23 2015-05-12 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4196303A (en) * 1978-03-20 1980-04-01 Scm Corporation d-Isomenthoxyacetic acid
JPS5538363A (en) * 1978-09-13 1980-03-17 Yoshitomi Pharmaceut Ind Ltd Preparation of optically active n-mercaptoacyl-imino acid

Also Published As

Publication number Publication date
CA2243542A1 (en) 1997-09-12
JP2000506162A (ja) 2000-05-23
DE69710051D1 (de) 2002-03-14
EP0885191B1 (en) 2002-01-23
MX9807266A (ja) 1999-08-31
DE69710051T2 (de) 2002-08-14
KR19990087441A (ko) 1999-12-27
ATE212336T1 (de) 2002-02-15
AU2102497A (en) 1997-09-22
KR100459149B1 (ko) 2005-06-10
CA2243542C (en) 2003-02-18
WO1997032851A1 (en) 1997-09-12
EP0885191A1 (en) 1998-12-23
ES2173422T3 (es) 2002-10-16
DK0885191T3 (da) 2002-05-06
AU700836B2 (en) 1999-01-14
PT885191E (pt) 2002-06-28
MX202728B (ja) 2001-06-29

Similar Documents

Publication Publication Date Title
JP4138005B2 (ja) トレオーメチルフェニデートの分割
JP4163748B2 (ja) O,o’―ビスアロイル酒石酸類によるメチルフェニデートの光学分割
KR100453707B1 (ko) 디-트레오-(알,알)-메틸페니데이트의제조방법및에피머화에의한불필요한거울상이성질체의재순환방법
US6242464B1 (en) Single isomer methylphenidate and resolution process
CA2200355C (en) Crystallisation of levobupivacaine and analogues thereof
US6121453A (en) Resolution of threo-methylphenidate
US6100401A (en) Process for preparing the d-threo isomer of methylphenidate hydrochloride
US5936091A (en) Processes and intermediates for resolving piperidyl acetamide stereoisomers
JPH10503752A (ja) ラセミ形α−〔4−(1,1−ジメチルエチル)フェニル〕−4−(ヒドロキシジフェニルメチル)−1−ピペリジンブタノールおよび誘導体化合物の光学分割に有用な方法およびジアステレオマー塩
US5965734A (en) Processes and intermediates for preparing 2-substituted piperidine stereoisomers
US6162919A (en) Process for preparing the d-threo isomer of methylphenidate hydrochloride
CA2291251A1 (en) Novel process
JPH0421662B2 (ja)
MXPA98007266A (en) Treo-metilfenid resolution
KR20190128663A (ko) 라세믹 3-알킬피페리딘-카르복실산 에틸 에스테르의 광학 이성질체를 분리하는 방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080108

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080507

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080605

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110613

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees